Lilly’s Obesity Pill to TOP Wegovy? SHOCKING Analyst Predictions!
Could a new weight loss pill dethrone the current market leader? Despite recent trial data that disappointed investors, analysts believe Eli Lilly's orforglipron could still rival Novo Nordisk's oral semaglutide. While Novo Nordisk's drug may offer slightly better weight loss, Eli Lilly’s pill boasts easier manufacturing, potentially lower costs, and no dietary restrictions. Moreover, experts highlight the significant market potential for both pills, emphasizing that even 12% weight loss can be a game-changer for many. Subscribe to our channel to stay updated on the latest developments in the weight loss drug race.
Tags/Hashtags: #obesity #orforglipron #wegovy #semaglutide #orforglipron #wegovy #ozempic #mounjaro #semaglutide #tirzepatide #pfizer #astrazeneca #roche
Leave a Reply